Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutation Cholangiocarcinoma
Condition(s):CholangiocarcinomaLast Updated:March 15, 2024Recruiting
Include Studies Not Open or Pending
Condition(s):CholangiocarcinomaLast Updated:March 15, 2024Recruiting
Condition(s):Advanced or Metastatic Solid TumorsLast Updated:March 15, 2024Recruiting
Condition(s):Arteriovenous MalformationsLast Updated:November 7, 2023Not yet recruiting
Condition(s):HistiocytosisLast Updated:January 17, 2024Recruiting
Condition(s):Metastatic Pancreatic Carcinoma; Stage II Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer; Unresectable Pancreatic CarcinomaLast Updated:February 28, 2024Recruiting
Condition(s):NSCLC; BRAF V600E Mutation; Advanced Cancer; Stage IIIB NSCLC; Stage IV NSCLCLast Updated:October 12, 2023Not yet recruiting
Condition(s):MelanomaLast Updated:June 8, 2023Recruiting
Condition(s):BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid TumorLast Updated:March 22, 2024Recruiting
Condition(s):MelanomaLast Updated:January 5, 2024Recruiting
Condition(s):Thyroid Gland Anaplastic CarcinomaLast Updated:February 4, 2021Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.